Cite

HARVARD Citation

    Reilley, M. et al. (2019). TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma. Journal for immunotherapy of cancer. 7 (1), p. . [Online]. 
  
Back to record